| # | Title | Journal | Year | Citations |
|---|
| 1 | Potential of fecal microbiota for early‐stage detection of colorectal cancer | Molecular Systems Biology | 2014 | 991 |
| 2 | Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review | Clinical Nutrition | 2018 | 252 |
| 3 | Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma | PLoS ONE | 2012 | 252 |
| 4 | Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes | Oncotarget | 2014 | 188 |
| 5 | Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients | British Journal of Cancer | 2012 | 170 |
| 6 | Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial | Annals of Oncology | 2012 | 164 |
| 7 | Posterior reversible encephalopathy syndrome induced by anti-VEGF agents | Targeted Oncology | 2011 | 117 |
| 8 | Recommendations for Bowel Obstruction With Peritoneal Carcinomatosis | Journal of Pain and Symptom Management | 2014 | 107 |
| 9 | Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO | British Journal of Cancer | 2013 | 100 |
| 10 | Sorafenib exposure decreases over time in patients with hepatocellular carcinoma | Investigational New Drugs | 2012 | 95 |
| 11 | Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis | Oncologist | 2012 | 91 |
| 12 | Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials | Journal of Clinical Oncology | 2021 | 84 |
| 13 | Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment | European Journal of Cancer | 2022 | 76 |
| 14 | Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib | Clinical Pharmacokinetics | 2019 | 72 |
| 15 | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study | Cancers | 2020 | 72 |
| 16 | An Observational Study of Bevacizumab-Induced Hypertension as a Clinical Biomarker of Antitumor Activity | Oncologist | 2011 | 70 |
| 17 | Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency | European Journal of Cancer | 2017 | 65 |
| 18 | Immunotherapy and patients treated for cancer with microsatellite instability | Bulletin Du Cancer | 2017 | 64 |
| 19 | Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome | Molecular Cancer Therapeutics | 2017 | 61 |
| 20 | Role of physical activity and sport in oncology | Critical Reviews in Oncology/Hematology | 2015 | 58 |
| 21 | Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer | Journal of the National Cancer Institute | 2021 | 56 |
| 22 | Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit | Cancer Treatment Reviews | 2012 | 55 |
| 23 | Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis | Journal of the American College of Cardiology | 2018 | 54 |
| 24 | Treatment of bevacizumab-induced hypertension by amlodipine | Investigational New Drugs | 2012 | 53 |
| 25 | BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? | Current Treatment Options in Oncology | 2017 | 51 |
| 26 | DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas | Clinical Cancer Research | 2016 | 47 |
| 27 | Impact of Physical Activity on Cancer-Specific and Overall Survival of Patients with Colorectal Cancer | Gastroenterology Research and Practice | 2013 | 45 |
| 28 | RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study | | 2020 | 43 |
| 29 | Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer | ESMO Open | 2021 | 42 |
| 30 | Platinum-sensitivity in metastatic colorectal cancer: Towards a definition | European Journal of Cancer | 2013 | 41 |
| 31 | Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells | British Journal of Cancer | 2008 | 40 |
| 32 | Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib | Medical Oncology | 2012 | 40 |
| 33 | NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas | Cancer Research | 2017 | 40 |
| 34 | Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR) | Journal of Clinical Oncology | 2020 | 40 |
| 35 | Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer | European Journal of Cancer | 2021 | 40 |
| 36 | Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer | Annals of Oncology | 2016 | 39 |
| 37 | Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study. | Journal of Clinical Oncology | 2022 | 39 |
| 38 | Cancer subtypes classification using long non-coding RNA | Oncotarget | 2016 | 38 |
| 39 | Four Distinct Health Profiles in Older Patients With Cancer: Latent Class Analysis of the Prospective ELCAPA Cohort | Journals of Gerontology - Series A Biological Sciences and Medical Sciences | 2016 | 36 |
| 40 | Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors | Clinical Genitourinary Cancer | 2019 | 34 |
| 41 | Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer | European Journal of Surgical Oncology | 2010 | 31 |
| 42 | PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy? | Annals of Oncology | 2018 | 31 |
| 43 | Comprehensive integrative profiling of upper tract urothelial carcinomas | Genome Biology | 2021 | 31 |
| 44 | ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy | Journal of Cancer | 2014 | 30 |
| 45 | Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial | International Journal of Radiation Oncology Biology Physics | 2016 | 28 |
| 46 | Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients? | Cancers | 2019 | 28 |
| 47 | VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption | Investigational New Drugs | 2011 | 25 |
| 48 | Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project | Annals of Oncology | 2015 | 25 |
| 49 | Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects? | Aids | 2020 | 25 |
| 50 | ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer | Journal of Clinical Oncology | 2023 | 25 |
